High Sporulation and Overexpression of Virulence Factors in Biofilms and Reduced Susceptibility to Vancomycin and Linezolid in Recurrent Clostridium [Clostridioides] Difficile Infection Isolates

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2019 Aug 1

PMID 31365590

Citations 14

Authors

Laura Tijerina-Rodriguez

Licet Villarreal-Trevino

Simon D Baines

Rayo Morfin-Otero

Adrian Camacho-Ortiz

Samantha Flores-Trevino

Hector Maldonado-Garza

Eduardo Rodriguez-Noriega

Elvira Garza-Gonzalez

Affiliations

Soon will be listed here.

Abstract

Clostridium [Clostridioides] difficile infection (CDI) is one of the leading causes of diarrhea associated with medical care worldwide, and up to 60% of patients with CDI can develop a recurrent infection (R-CDI). A multi-species microbiota biofilm model of C. difficile was designed to evaluate the differences in the production of biofilms, sporulation, susceptibility to drugs, expression of sporulating (sigH, spo0A), quorum sensing (agrD1, and luxS), and adhesion-associated (slpA and cwp84) pathway genes between selected C. difficile isolates from R-CDI and non-recurrent patients (NR-CDI). We obtained 102 C. difficile isolates from 254 patients with confirmed CDI (66 from NR-CDI and 36 from R-CDI). Most of the isolates were biofilm producers, and most of the strains were ribotype 027 (81.374%, 83/102). Most C. difficile isolates were producers of biofilm (100/102), and most were strongly adherent. Sporulation was higher in the R-CDI than in the NR-CDI isolates (p = 0.015). The isolates from R-CDI patients more frequently demonstrated reduced susceptibility to vancomycin than isolates of NR-CDI patients (27.78% [10/36] and 9.09% [6/66], respectively, p = 0.013). The minimum inhibitory concentrations for vancomycin and linezolid against biofilms (BMIC) were up to 100 times and 20 times higher, respectively, than the corresponding planktonic MICs. Expression of sigH, spo0A, cwp84, and agrD1 was higher in R-CDI than in NR-CDI isolates. Most of the C. difficile isolates were producers of biofilms with no correlation with the ribotype. Sporulation was greater in R-CDI than in NR-CDI isolates in the biofilm model of C. difficile. The R-CDI isolates more frequently demonstrated reduced susceptibility to vancomycin and linezolid than the NR-CDI isolates in both planktonic cells and biofilm isolates. A higher expression of sporulating pathway (sigH, spo0A), quorum sensing (agrD1), and adhesion-associated (cwp84) genes was found in R-CDI than in NR-CDI isolates. All of these factors can have effect on the recurrence of the infection.

Citing Articles

Regulatory networks: Linking toxin production and sporulation in Clostridioides difficile.

Hasan M, Alaribe O, Govind R Anaerobe. 2024; 91:102920.

PMID: 39521117 PMC: 11811957. DOI: 10.1016/j.anaerobe.2024.102920.

RelQ-mediated alarmone signalling regulates growth, stress-induced biofilm formation and spore accumulation in .

Malik A, Oludiran A, Poudel A, Alvarez O, Woodward C, Purcell E Microbiology (Reading). 2024; 170(7).

PMID: 39028551 PMC: 11317968. DOI: 10.1099/mic.0.001479.

RelQ-mediated alarmone signaling regulates growth, sporulation, and stress-induced biofilm formation in .

Malik A, Oludiran A, Poudel A, Alvarez O, Woodward C, Purcell E bioRxiv. 2024; .

PMID: 38405794 PMC: 10888890. DOI: 10.1101/2024.02.14.580318.

Characterization of community-acquired strains in Israel, 2020-2022.

Schwartz O, Rohana H, Azrad M, Shor A, Rainy N, Maor Y Front Microbiol. 2024; 14:1323257.

PMID: 38169783 PMC: 10758451. DOI: 10.3389/fmicb.2023.1323257.

Review of the Impact of Biofilm Formation on Recurrent Infection.

Rubio-Mendoza D, Martinez-Melendez A, Maldonado-Garza H, Cordova-Fletes C, Garza-Gonzalez E Microorganisms. 2023; 11(10).

PMID: 37894183 PMC: 10609348. DOI: 10.3390/microorganisms11102525.

References

Bidet P, Barbut F, Lalande V, Burghoffer B, Petit J . Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing. FEMS Microbiol Lett. 1999; 175(2):261-6. DOI: 10.1111/j.1574-6968.1999.tb13629.x. View

McFarland L, Elmer G, Surawicz C . Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002; 97(7):1769-75. DOI: 10.1111/j.1572-0241.2002.05839.x. View

Goldstein E, Citron D, Merriam C, Warren Y, Tyrrell K, Fernandez H . In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother. 2002; 47(1):337-41. PMC: 148963. DOI: 10.1128/AAC.47.1.337-341.2003. View

Chang L, Chen H, Chang C, Lee T, Wu W . Contribution of integrons, and SmeABC and SmeDEF efflux pumps to multidrug resistance in clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother. 2004; 53(3):518-21. DOI: 10.1093/jac/dkh094. View

Lemee L, Dhalluin A, Testelin S, Mattrat M, Maillard K, Lemeland J . Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol. 2004; 42(12):5710-4. PMC: 535266. DOI: 10.1128/JCM.42.12.5710-5714.2004. View

Pelaez T, Alcala L, Alonso R, Martin-Lopez A, Garcia-Arias V, Marin M . In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother. 2005; 49(3):1157-9. PMC: 549223. DOI: 10.1128/AAC.49.3.1157-1159.2005. View

Freeman J, Stott J, Baines S, Fawley W, Wilcox M . Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. J Antimicrob Chemother. 2005; 56(5):988-9. DOI: 10.1093/jac/dki357. View

Stepanovic S, Vukovic D, Hola V, Di Bonaventura G, Djukic S, Cirkovic I . Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS. 2007; 115(8):891-9. DOI: 10.1111/j.1600-0463.2007.apm_630.x. View

Deneve C, Delomenie C, Barc M, Collignon A, Janoir C . Antibiotics involved in Clostridium difficile-associated disease increase colonization factor gene expression. J Med Microbiol. 2008; 57(Pt 6):732-738. DOI: 10.1099/jmm.0.47676-0. View

10.

OConnor J, Galang M, Sambol S, Hecht D, Vedantam G, Gerding D . Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 2008; 52(8):2813-7. PMC: 2493101. DOI: 10.1128/AAC.00342-08. View

11.

Baines S, OConnor R, Freeman J, Fawley W, Harmanus C, Mastrantonio P . Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother. 2008; 62(5):1046-52. DOI: 10.1093/jac/dkn313. View

12.

Karlsson S, Burman L, Akerlund T . Induction of toxins in Clostridium difficile is associated with dramatic changes of its metabolism. Microbiology (Reading). 2008; 154(Pt 11):3430-3436. DOI: 10.1099/mic.0.2008/019778-0. View

13.

Lawley T, Croucher N, Yu L, Clare S, Sebaihia M, Goulding D . Proteomic and genomic characterization of highly infectious Clostridium difficile 630 spores. J Bacteriol. 2009; 191(17):5377-86. PMC: 2725610. DOI: 10.1128/JB.00597-09. View

14.

Lawley T, Clare S, Walker A, Goulding D, Stabler R, Croucher N . Antibiotic treatment of clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immun. 2009; 77(9):3661-9. PMC: 2737984. DOI: 10.1128/IAI.00558-09. View

15.

Saujet L, Monot M, Dupuy B, Soutourina O, Martin-Verstraete I . The key sigma factor of transition phase, SigH, controls sporulation, metabolism, and virulence factor expression in Clostridium difficile. J Bacteriol. 2011; 193(13):3186-96. PMC: 3133256. DOI: 10.1128/JB.00272-11. View

16.

Donelli G, Vuotto C, Cardines R, Mastrantonio P . Biofilm-growing intestinal anaerobic bacteria. FEMS Immunol Med Microbiol. 2012; 65(2):318-25. DOI: 10.1111/j.1574-695X.2012.00962.x. View

17.

Deakin L, Clare S, Fagan R, Dawson L, Pickard D, West M . The Clostridium difficile spo0A gene is a persistence and transmission factor. Infect Immun. 2012; 80(8):2704-11. PMC: 3434595. DOI: 10.1128/IAI.00147-12. View

18.

Figueroa I, Johnson S, Sambol S, Goldstein E, Citron D, Gerding D . Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis. 2012; 55 Suppl 2:S104-9. PMC: 3388025. DOI: 10.1093/cid/cis357. View

19.

Paredes-Sabja D, Cofre-Araneda G, Brito-Silva C, Pizarro-Guajardo M, Sarker M . Clostridium difficile spore-macrophage interactions: spore survival. PLoS One. 2012; 7(8):e43635. PMC: 3428350. DOI: 10.1371/journal.pone.0043635. View

20.

apa T, Dapa T, Leuzzi R, Ng Y, Baban S, Adamo R . Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile. J Bacteriol. 2012; 195(3):545-55. PMC: 3554014. DOI: 10.1128/JB.01980-12. View